Latest ArticlesTo evaluate the cost-effectiveness of osimertinib for adjuvant treatment of patients with epidermal grouth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) after tumor resection from the perspective of Chinese healthcare system.
A 5-state Markov model with 1-month cycle was constructed, and the lifetime horizon was used. Data on patient baseline characteristics, transition probabilities, incidence of adverse events and health utilities were mainly derived from ADAURA study, supplemented by CancerLinQ database, FLAURA study and published literatures. Medical costs were derived from Chinese government documents, literature, and clinical expert surveys. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis were conducted simultaneously.
Base-case analysis results showed that for patients with EGFR mutation-positive NSCLC after tumor resection, the incremental cost of osimertinib compared with placebo was 25 395.25 yuan, the incremental quality adjusted life year (QALY) was 3.25, the incremental cost-effectiveness ratio (ICER) was 7 812.45 yuan/QALY, which was much lower than 1 times Chinese per capita GDP (72 447.00 yuan in 2020). Osimertinib has cost-effectiveness. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis indicated that base-case analysis results were robust.
Under the threshold of 1-time Chinese per capita GDP, osimertinib was predicted to be the cost-effective treatment option compared with placebo for patients with EGFR mutation-positive NSCLC after tumor resection in China.
To explore the feasibility of different point urinary sodium formula to evaluate 24-hour urinary sodium excretion.
A total of 226 inpatients in the department of hypertension, northern area of Ruijin hospital from May to December 2016 were analyzed retrospectively. Point urine and 24-hour urinary sodium excretion was estimated by three point urine sodium formulas, Sun C method, Kawasaki method and Tanaka method. The differences between 24h urinary sodium estimated value and measured value were compared by paired rank sum test. The consistency of 24-hour urinary sodium estimated value and measured value was evaluated by Bland-Altman method.
There were significant differences between the estimated 24-hour urinary sodium [Sun C method 137.4 (111.0, 161.8) mmol/d, Kawasaki method 170.7 (120.0, 217.0)mmol/d, Tanaka method 136.9 (105.4, 166.4)mmol/d] and the actual measured value [142.7 (103.8, 183.5) mmol/d](P<0.05). In male patients, the difference between 24-hour urinary sodium estimated by Sun C method and the actual measured value was the smallest, and there was no significant difference between them (P>0.05). In female patients, there was no significant difference between the estimated 24-hour urinary sodium by Kawasaki method and Tanaka method compared to the actual measured value (P>0.05), while there was significant difference between 24-hour urinary sodium estimated by Sun C method and the actual measured value (P<0.05).
The hospitalized patients with hypertension in our hospital, the reliability of 24-hour urinary sodium estimated by the three formulas is not high. After grouping according to gender, Sun C method has higher significance estimation of hospitalized male patients than female patients.
To observe the predictive effect of osteoporosis self-assessment tool for Asians (OSTA) on osteoporosis (OP) in peritoneal dialysis (PD) patients.
A total of 145 PD patients who underwent bone mineral density (BMD) testing were selected from department of nephrology, Ruijin hospital affiliated to Shanghai Jiao Tong university school of medicine from January 2013 to January 2014. Dual energy X-ray absorptiometry was used to evaluate the incidence of OP in PD patients. PD patients were divided into low-risk group (n=98), medium-risk group (n=33) and high-risk group (n=14) by OSTA index. The BMD levels of the three groups were compared to evaluate the clinical value of OSTA. The levels of serum calcium, phosphorus and parathyroid hormone (PTH) were compared between OP patients and non OP patients, and the independent risk factors of OP were analyzed.
The incidence of OP in female lumbar spine and hip were 14.81% and 11.11%, respectively, and the osteopenia were 25.93% and 48.15%. The incidence of OP in male lumbar spine and hip was 2.44% and 2.38%, and the osteopenia were 26.83% and 20.24%. The detection rates of OP in patients over 65 years old in lumbar and hip were 11.11% and 13.33%, respectively, and the osteopenia were 33.33% and 40.00%. The detection rates of OP in patients under 65 years old in lumbar and hip were 6.00% and 2.00%, respectively, and the osteopenia were by 22.00% and 29.00%. Female and elevated PTH are independent risk factors for OP. According to OSTA index grouping, the detection rates of OP in the lumbar and hip joint in the low-risk group were 5.10% and 1.02%, 12.12% and 12.12% in the medium-risk group, 14.29% and 21.43% in the high-risk group.
The incidence of OP and osteopenia in PD patients was higher, especially in female and the elderly. Poor control of PTH and the female were independent risk factors for OP. The screening effect of OP in PD patients by OSTA index is not effective, which needs to be further improved and verified in clinical application.
To study the predictive value of reduced flow-mediated dilatation (FMD) by brachial artery flow in the occurrence of coronary atherosclerotic heart disease (CHD).
A total of 200 patients who underwent coronary angiography in Shanghai Xuhui district central hospital from January to December 2019 were selected. According to the results of coronary angiography, 154 patients with CHD were divided to the CHD group which included a single vessel, two-vessel and three-vessel group. And the other 46 people without CHD were selected as the control group. Age, hypertension, smoking history and diabetes history were collected. The level of FMD, peripheral venous blood, blood pressure (systolic blood pressure, diastolic blood pressure) were gathered in all patients. Statistical method was used to compare the FMD in the two groups of patients, and the relationship between FMD and CHD was analyzed.
The level of FMD in CHD group was markedly lower than that in control group. The logistic regression analysis showed that decreased FMD was an independent risk factor for CHD, and FMD decreased with the increasing number of diseased coronary branches. Correlation analysis showed that in CHD patients FMD was negatively correlated with CHD risk factors, and positively correlated with high-density lipoprotein.
The level of FMD was negatively with the severity of coronary atherosclerosis, and the decrease of FMD was an independent risk factor for CHD. Reduced FMD can predict the occurrence of coronary heart disease.
To investigate effects of maternal triglyceride (TG) levels on large for gestational age infants (LGA) in the second trimester of pregnancy (24-28 weeks).
A total of 9 096 pregnant women with non-gestational diabetes mellitus who delivered a single live fetus in the maternal and child health hospital, Songjiang district from January 2018 to January 2019 were enrolled. Fasting plasma TG levels were measured during 24-28 weeks of pregnancy. According to the birth weight, they were divided into LGA group (n=1 068) and non-LGA group (n=8 028). Chi-square test and multivariate logistic regression analysis were used to analyze the effects of TG on LGA.
There were significant differences in maternal age, pre-pregnancy body mass index, parity, fetal sex and TG levels between LGA group and non-LGA group (P<0.05). Chi-square test showed that overweight and obesity before pregnancy, postpartum, neonatal male and maternal high TG levels increased the risk of LGA (P<0.05). The results of multivariate logistic regression analysis showed that after controlling the influence of other factors, the high TG level (TG≥2.67 mmol/L) increased the risk of LGA, which was statistically significant (odds ratio=1.36, 95% confidence interval: 1.13-1.64).
High maternal TG levels in the second trimester of pregnancy will increase the risk of LGA. Strengthening supervision of pregnant women with high TG levels in the second trimester of pregnancy may help to reduce the incidence of LGA.
To evaluate the efficacy and safety of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome by meta analysis.
China National Knowledge Infrastructure, Wanfang, Chongqing VIP, China Biomedical Literature Database, PubMed, Cochrane Library, Embase and other databases were searched to collect randomized controlled trials of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome from the establishment of the database to December 2020. Two researchers assessed the risk of bias and quality of selected literature according to the Cochrane5.1 manual. State/SE15.1 software was used for meta analysis.
Finally, 13 studies involving 953 patients with psoriasis were included. The results of meta analysis showed that compared with the control group, the total effective rate [odds ratio (OR)=3.03, 95% confidence interval (CI): 2.04-4.48, P<0.000 1)], psoriasis area and severity index (PASI) score (standardized mean difference=-0.68, 95% CI: -0.97--0.39, P<0.000 1) and adverse reactions of the treatment group (OR=0.32, 95%CI: 0.17-0.60, P<0.000 1) were better than those of the control group.
The method of efficacy and safety of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome can reduce the PASI score and improve the skin lesions, with definite curative effect and high safety.
Homozygous familial hypercholesterolaemia (HoFH) is a severe and rare hypercholesterolemia, which is characterized by a significant increase in low density lipoprotein-cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. At present, evinacumab, mipomersen, lomitapid and proprotein convertase subtilisin/kexin type 9 inhibitors have been approved for the treatment of HoFH, which effectively solves the problem of the lack of drugs for rare diseases. The article briefly reviewed the clinical research progress on drugs for the treatment of HoFH.
National Medical Products Administration approved the import of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) in April 2021. As a long-acting GLP-1RA, this product has demonstrated its efficacy and safety through pharmacokinetic studies, SUSTAIN studies and SURE studies before listing. Levels of blood glucose and glycosylated hemoglobin can be reduced with lower incidence of hypoglycemia, lower body weight and lower risk of cardiovascular disease. This article summarized the main clinical research data of semaglutide and relative mechanisms in the treatment of type 2 diabetes mellitus, providing reference for clinical use of semaglutide.